{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:52:26Z","timestamp":1789901546047,"version":"4.0.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.therap.2016.02.024","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T14:33:08Z","timestamp":1458311588000},"page":"365-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Atteintes r\u00e9tiniennes iatrog\u00e8nes\u00a0: \u00e9tude cas\/non cas dans la banque nationale de pharmacovigilance"],"prefix":"10.1016","volume":"71","author":[{"given":"Nicolas","family":"Bourgeois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Chavant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lafay-Chebassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Leveziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"P\u00e9rault-Pochat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.therap.2016.02.024_bib0380","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1517\/14740338.3.3.249","article-title":"Drugs and the retina","volume":"3","author":"Constable","year":"2004","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"10.1016\/j.therap.2016.02.024_bib0385","first-page":"1203","article-title":"The effects of medications on the eyes","volume":"56","author":"Labetoulle","year":"2006","journal-title":"Rev Prat"},{"issue":"5","key":"10.1016\/j.therap.2016.02.024_bib0390","first-page":"293","article-title":"Retinopathy induced by drugs and herbal medicines","volume":"12","author":"Nencini","year":"2008","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.therap.2016.02.024_bib0395","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archopht.1994.01090130102026","article-title":"Hypertension and retinopathy, arteriolar narrowing, and arteriovenous nicking in a population","volume":"112","author":"Klein","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.therap.2016.02.024_bib0400","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/archopht.121.2.245","article-title":"Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study","volume":"121","author":"Van Leiden","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.therap.2016.02.024_bib0405","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0161-6420(02)01931-0","article-title":"The prevalence and risk factors of retinal microvascular abnormalities in older persons: the Cardiovascular Health Study","volume":"110","author":"Wong","year":"2003","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.therap.2016.02.024_bib0410","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/archopht.116.1.83","article-title":"Retinopathy in older persons without diabetes and its relationship to hypertension","volume":"116","author":"Yu","year":"1998","journal-title":"Arch Ophthalmol"},{"issue":"304","key":"10.1016\/j.therap.2016.02.024_bib0415","first-page":"15","article-title":"Classification and profile of adverse drug effects","author":"Cordonnier","year":"2007","journal-title":"Bull Soc Belge Ophtalmol"},{"key":"10.1016\/j.therap.2016.02.024_bib0420","first-page":"6","article-title":"Retinal toxicities caused by systemic medications","author":"Lin","year":"2007","journal-title":"Retinal Physician"},{"issue":"2","key":"10.1016\/j.therap.2016.02.024_bib0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0246-0343(12)54040-2","article-title":"Atteintes ophtalmiques d\u2019origine m\u00e9dicamenteuse","volume":"9","author":"Rousseau","year":"2012","journal-title":"Ophtalmologie"},{"issue":"6","key":"10.1016\/j.therap.2016.02.024_bib0430","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1365-2125.2011.04009.x","article-title":"Memory disorders associated with consumption of drugs: updating through a case\/noncase study in the French PharmacoVigilance Database","volume":"72","author":"Chavant","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.therap.2016.02.024_bib0435","first-page":"507","article-title":"Drug-induced dementia: a case\/non-case study in the French Pharmacovigilance database","volume":"62","author":"Favreliere","year":"2007","journal-title":"Therapie"},{"issue":"6","key":"10.1016\/j.therap.2016.02.024_bib0440","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","article-title":"French pharmacovigilance database system: examples of utilisation","volume":"50","author":"Moore","year":"1995","journal-title":"Therapie"},{"issue":"8463","key":"10.1016\/j.therap.2016.02.024_bib0445","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(85)90918-3","article-title":"Adverse drug reaction monitoring: doing it the French way","volume":"2","author":"Moore","year":"1985","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.therap.2016.02.024_bib0450","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2016.02.024_bib0455","series-title":"Guide d\u2019introduction aux SMQs Version 17.0","year":"2014"},{"issue":"2","key":"10.1016\/j.therap.2016.02.024_bib0460","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France","volume":"40","author":"Begaud","year":"1985","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.therap.2016.02.024_bib0465","first-page":"128","article-title":"Branch retinal vein occlusion","volume":"20","author":"Hamid","year":"2008","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"10.1016\/j.therap.2016.02.024_bib0470","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005021.pub2","article-title":"Haemodilution for retinal vein occlusion","volume":"5","author":"Rennie","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.therap.2016.02.024_bib0475","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0181-5512(05)81135-0","article-title":"Risk factors for diabetic macular edema","volume":"28","author":"Jeddi Blouza","year":"2005","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.therap.2016.02.024_bib0480","series-title":"D\u00e9collements de r\u00e9tine","first-page":"545","article-title":"\u00c9pid\u00e9miologie","author":"Baeteman","year":"2012"},{"issue":"1","key":"10.1016\/j.therap.2016.02.024_bib0485","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0161-6420(95)31052-4","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema","volume":"102","author":"Klein","year":"1995","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.therap.2016.02.024_bib0490","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ophtha.2008.10.016","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1\u00a0diabetes","volume":"116","author":"Klein","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.therap.2016.02.024_bib0495","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study","volume":"98","author":"Klein","year":"2000","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"2","key":"10.1016\/j.therap.2016.02.024_bib0500","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archopht.1982.01030030291012","article-title":"Epidemiology of retinal detachment","volume":"100","author":"Haimann","year":"1982","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.therap.2016.02.024_bib0505","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1001\/archopht.116.3.297","article-title":"United Kingdom Prospective Diabetes Study 30\u00a0diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors","volume":"116","author":"Kohner","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.therap.2016.02.024_bib0510","series-title":"Martindale. The complete drug reference","year":"2009"},{"key":"10.1016\/j.therap.2016.02.024_bib0515","unstructured":"Base de donn\u00e9es publique des m\u00e9dicaments. RCP. http:\/\/base-donnees-publique.medicaments.gouv.fr\/ [Consult\u00e9 le 21\u00a0d\u00e9cembre 2015]."},{"issue":"3","key":"10.1016\/j.therap.2016.02.024_bib0520","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/15569527.2014.938751","article-title":"Early effect of hydroxychloroquine therapy: relationship between cumulative dose and retinal thickness","volume":"34","author":"Agarwal","year":"2015","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.therap.2016.02.024_bib0525","series-title":"\u00ab\u00a0Ophtalmologie\u00a0\u00bb INTERnat MEDecine","year":"1999"},{"issue":"1","key":"10.1016\/j.therap.2016.02.024_bib0530","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/jop.2006.0083","article-title":"Intravitreal toxicity of high-dose etanercept","volume":"23","author":"Kivilcim","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"issue":"Suppl.\u00a0II","key":"10.1016\/j.therap.2016.02.024_bib0535","first-page":"381","article-title":"Retinal toxicity due to etanercept","volume":"67","author":"Simsek","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.therap.2016.02.024_bib0540","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0896-1549(02)00051-2","article-title":"Medications and retinal toxicity","volume":"15","author":"Schwartz","year":"2002","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1016\/j.therap.2016.02.024_bib0545","unstructured":"EMA Procedural steps taken and scientific information after the authorisation for IntronA. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation\/human\/000281\/WC500034850.pdf [Consult\u00e9 le 21\u00a0d\u00e9cembre 2015 (24\u00a0pages)]."},{"issue":"6","key":"10.1016\/j.therap.2016.02.024_bib0550","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s10384-009-0738-8","article-title":"Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin","volume":"53","author":"Kim","year":"2009","journal-title":"Jpn J Ophthalmol"},{"issue":"9","key":"10.1016\/j.therap.2016.02.024_bib0555","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/jvh.12135","article-title":"Interferon-associated retinopathy during the treatment of chronic hepatitis C: a systematic review","volume":"20","author":"Raza","year":"2013","journal-title":"J Viral Hepat"},{"issue":"23","key":"10.1016\/j.therap.2016.02.024_bib0560","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.3748\/wjg.v12.i23.3756","article-title":"Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C","volume":"12","author":"Okuse","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.therap.2016.02.024_bib0565","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hep.25654","article-title":"Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening","volume":"56","author":"Vujosevic","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.therap.2016.02.024_bib0570","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1034\/j.1600-0676.2001.021003192.x","article-title":"Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C","volume":"21","author":"Saito","year":"2001","journal-title":"Liver"},{"issue":"3","key":"10.1016\/j.therap.2016.02.024_bib0575","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/archopht.1993.01090030068041","article-title":"Interferon-associated retinopathy","volume":"111","author":"Guyer","year":"1993","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.therap.2016.02.024_bib0580","first-page":"309","article-title":"Retinal complications during interferon therapy for chronic hepatitis C","volume":"91","author":"Kawano","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.therap.2016.02.024_bib0585","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/bjo.79.2.150","article-title":"Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa","volume":"79","author":"Hayasaka","year":"1995","journal-title":"Br J Ophthalmol"},{"issue":"4443","key":"10.1016\/j.therap.2016.02.024_bib0590","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.6154315","article-title":"Inhibition of cell motility by interferon","volume":"208","author":"Brouty-Boye","year":"1980","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.therap.2016.02.024_bib0595","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1083\/jcb.104.3.689","article-title":"Inhibition of endothelial cell proliferation by gamma-interferon","volume":"104","author":"Friesel","year":"1987","journal-title":"J Cell Biol"},{"issue":"19","key":"10.1016\/j.therap.2016.02.024_bib0600","first-page":"5155","article-title":"Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses","volume":"47","author":"Sidky","year":"1987","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.therap.2016.02.024_bib0605","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0161-6420(93)31712-4","article-title":"Regression of experimental iris neovascularization with systemic alpha-interferon","volume":"100","author":"Miller","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1016\/j.therap.2016.02.024_bib0610","unstructured":"RCP ATU cohorte Aprokam (c\u00e9furoxime). http:\/\/www.ansm.sante.fr [Consult\u00e9 le 21\u00a0d\u00e9cembre 2015]."},{"issue":"11","key":"10.1016\/j.therap.2016.02.024_bib0615","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.jcrs.2010.07.007","article-title":"Early serous macular detachment after phacoemulsification surgery","volume":"36","author":"Buyukyildiz","year":"2010","journal-title":"J Cataract Refract Surg"},{"issue":"2","key":"10.1016\/j.therap.2016.02.024_bib0620","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcrs.2010.08.047","article-title":"Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery","volume":"37","author":"Delyfer","year":"2011","journal-title":"J Cataract Refract Surg"},{"issue":"6","key":"10.1016\/j.therap.2016.02.024_bib0625","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jcrs.2011.03.032","article-title":"Macular infarction after inadvertent intracameral cefuroxime","volume":"37","author":"Qureshi","year":"2011","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.therap.2016.02.024_bib0630","first-page":"77","article-title":"Crystalline retinopathy","volume":"304","author":"Rasquin","year":"2007","journal-title":"Bull Soc Belge Ophtalmol"},{"issue":"10","key":"10.1016\/j.therap.2016.02.024_bib0635","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1001\/archopht.120.10.1402","article-title":"Tamoxifen maculopathy","volume":"120","author":"Alwitry","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"10.1016\/j.therap.2016.02.024_bib0640","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(19920615)69:12<2961::AID-CNCR2820691215>3.0.CO;2-W","article-title":"Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63\u00a0patients","volume":"69","author":"Pavlidis","year":"1992","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.therap.2016.02.024_bib0645","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/cncr.21651","article-title":"Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials","volume":"106","author":"Gianni","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.therap.2016.02.024_bib0650","article-title":"Estrog\u00e8nes","author":"Allain","year":"2008","journal-title":"Pharmacorama"},{"issue":"6","key":"10.1016\/j.therap.2016.02.024_bib0655","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1444-0938.2012.00771.x","article-title":"Macular oedema due to letrozole: a first case report","volume":"95","author":"Moschos","year":"2012","journal-title":"Clin Exp Optom"},{"issue":"5","key":"10.1016\/j.therap.2016.02.024_bib0660","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/OPX.0b013e31816bea3b","article-title":"Retinal hemorrhages in anastrozole users","volume":"85","author":"Eisner","year":"2008","journal-title":"Optom Vis Sci"},{"issue":"9453","key":"10.1016\/j.therap.2016.02.024_bib0665","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5\u00a0years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.therap.2016.02.024_bib0670","first-page":"1375","article-title":"Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec\u00ae) in a patient being treated for gastrointestinal stromal tumor (GIST)","volume":"32","author":"Gulati","year":"2012","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.therap.2016.02.024_bib0675","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/sj.eye.6703092","article-title":"Histologic studies of the intraocular toxicity of imatinib mesylate in rabbits","volume":"22","author":"Kitzmann","year":"2008","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.therap.2016.02.024_bib0680","first-page":"1599","article-title":"Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase\/Akt survival signaling in RGC-5\u00a0retinal ganglion cells","volume":"15","author":"Biswas","year":"2009","journal-title":"Mol Vis"},{"issue":"18","key":"10.1016\/j.therap.2016.02.024_bib0685","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.therap.2016.02.024_bib0690","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/toxsci\/kfu213","article-title":"Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition","volume":"143","author":"Liu","year":"2015","journal-title":"Toxicol Sci"},{"issue":"373","key":"10.1016\/j.therap.2016.02.024_bib0695","first-page":"827","article-title":"Pazopanib\u00a0: d\u00e9collements de r\u00e9tine","volume":"34","year":"2014","journal-title":"Rev Prescrire"},{"key":"10.1016\/j.therap.2016.02.024_bib0700","series-title":"Product Information: PROCRIT Amgen, Inc","year":"2010"},{"key":"10.1016\/j.therap.2016.02.024_bib0705","series-title":"Product Information: RETACRIT Hospira UK Limited (per EMA)","year":"2011"},{"key":"10.1016\/j.therap.2016.02.024_bib0710","series-title":"Product Information: EPOGEN Amgen","year":"2011"},{"key":"10.1016\/j.therap.2016.02.024_bib0715","series-title":"Product Information: SILAPO Stada Arzneimittel AG (per EMA)","year":"2012"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.therap.2016.02.024_bib0720","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.earlhumdev.2011.01.027","article-title":"Erythropoietin and retinopathy of prematurity","volume":"87","author":"Romagnoli","year":"2011","journal-title":"Early Hum Dev"},{"issue":"8","key":"10.1016\/j.therap.2016.02.024_bib0725","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1056\/NEJMoa041773","article-title":"Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy","volume":"353","author":"Watanabe","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.therap.2016.02.024_bib0730","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1097\/IAE.0b013e3181d37539","article-title":"Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema","volume":"30","author":"Stahl","year":"2010","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.therap.2016.02.024_bib0735","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.addr.2006.07.024","article-title":"Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics","volume":"58","author":"Mannermaa","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.therap.2016.02.024_bib0740","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/01926230601178199","article-title":"An overview on the toxic morphological changes in the retinal pigment epithelium after systemic compound administration","volume":"35","author":"Mecklenburg","year":"2007","journal-title":"Toxicol Pathol"},{"issue":"7","key":"10.1016\/j.therap.2016.02.024_bib0745","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/153537020422900704","article-title":"Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy","volume":"229","author":"Toler","year":"2004","journal-title":"Exp Biol Med (Maywood)"},{"issue":"2","key":"10.1016\/j.therap.2016.02.024_bib0375","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00002018-200831020-00003","article-title":"Drug-induced ocular disorders","volume":"31","author":"Li","year":"2008","journal-title":"Drug Saf"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716000494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716000494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T09:17:26Z","timestamp":1600334246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716000494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0040595716000494"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2016.02.024","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atteintes r\u00e9tiniennes iatrog\u00e8nes\u00a0: \u00e9tude cas\/non cas dans la banque nationale de pharmacovigilance","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2016.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}